Lipocine Updates Corporate Presentation, Outlines Key Milestones for PPD Program
LPCN has more than doubled off its 52-week low of $2.52.
Summary
Lipocine Inc. filed an updated corporate presentation, providing a timeline for its lead postpartum depression (LPCN 1154) program, including topline Phase 3 results expected in early Q2 2026 and NDA submission targeted for mid-2026.
Key Events · Product Development and Regulatory · LPCN
-
Phase 3 Topline Results Expected
The company anticipates topline results from its pivotal Phase 3 trial for LPCN 1154 in postpartum depression (PPD) in early Q2 2026.
-
NDA Submission Targeted
Lipocine aims to submit a New Drug Application (NDA) for LPCN 1154 via the streamlined 505(b)(2) pathway in mid-2026.
-
Pipeline Updates
The presentation also provides updates on other pipeline candidates, including LPCN 2201 for Major Depressive Disorder, LPCN 2203 for Essential Tremor, and LPCN 2101 for Drug-Resistant Epilepsy.
Analysis · LPCN · Life Sciences
This updated corporate presentation provides investors with a clear roadmap for Lipocine's lead asset, LPCN 1154, following the recent completion of the Last Patient Last Visit in its pivotal Phase 3 trial. The outlined timeline for topline results in early Q2 2026 and a subsequent NDA filing in mid-2026 offers critical visibility into the company's near-term catalysts. For a small-cap biotech, these specific milestones are highly important for valuation and investor sentiment, indicating a defined path towards potential commercialization. The presentation also reiterates the broader pipeline, reinforcing the company's strategic direction.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 29.3% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LPCN was trading at $9.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.1M. The 52-week trading range was $2.52 to $12.37. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.